Ankit Singh Tomar
Research Subjects
Ankit Singh Tomar has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Paul T. Finger
The Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, New York
6 shared publications - Adriana Fandiño
Hospital de Pediatria JP Garrahan, Buenos Aires, Buenos Aires, Argentina
3 shared publications - Ashwin Mallipatna
Department of Ophthalmology & Vision Sciences, The Hospital for Sick Children, Toronto, Canada
3 shared publications - Denis P. Volodin
Ocular Oncology Department, The SN Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
3 shared publications - E. S. Kotova
National Medical Research Center Academician S.N. Fyodorov Intersectoral Scientific and Technical Complex “Eye microsurgery”, Ministry of Health of Russia
3 shared publications - Elisa Carreras
Universitat Autònoma de Barcelona, Barcelona, Spain ; Instituto Barraquer, Barcelona, Spain
3 shared publications
Latest Publications
- Open Access
- 15 November 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (2) , 422-428
Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy
- 15 November 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (2) , 422-428
Open AccessIntravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy
- Open Access
- 30 July 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (12) , 1409-1416
Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study
Background To determine the unique clinical characteristics and treatment outcomes of diffuse infiltrating retinoblastoma (DIR). Methods This international, multicentre, registry-based retrospective case series analysed pooled data from January 2001 to December 2013, including 132 eyes from 132 patients with DIR. Results Among 2854 eyes with retinoblastoma, 132 (4.6%; 95% CI, 3.9 to 5.5) had DIR. The median age at diagnosis for DIR patients was 24 months (IQR, 15–33), with no bilateral cases of DIR. The American Joint Committee on Cancer staging showed 4.5% cT2 and 95.5% cT3 categories, with no cT1 or cT4 cases. Clinical features associated with DIR included secondary glaucoma (67%), retinal detachment (38%), diffuse vitreous seeds (37%), anterior segment involvement (24%), vitreous haemorrhage (50%) and hyphema (6%). Primary enucleation was the predominant treatment (81%), while 19% initially received systemic chemotherapy, with 6% requiring subsequent enucleation. The 5-year Kaplan-Meier survival rate for cT3 DIR was 82% (95% CI, 78 to 86), significantly lower than the 94% (95% CI, 93 to 95) for cT3 non-DIR cases (pConclusions Approximately 1 in 20 patients with retinoblastoma had DIR, which often presented with glaucoma, anterior segment involvement or intraocular bleeding. DIR was more lethal than non-DIR cT3, with enucleation revealing high-risk pathology.
- 30 July 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (12) , 1409-1416
Open AccessDiffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study
Background To determine the unique clinical characteristics and treatment outcomes of diffuse infiltrating retinoblastoma (DIR). Methods This international, multicentre, registry-based retrospective case series analysed pooled data from January 2001 to December 2013, including 132 eyes from 132 patients with DIR. Results Among 2854 eyes with retinoblastoma, 132 (4.6%; 95% CI, 3.9 to 5.5) had DIR. The median age at diagnosis for DIR patients was 24 months (IQR, 15–33), with no bilateral cases of DIR. The American Joint Committee on Cancer staging showed 4.5% cT2 and 95.5% cT3 categories, with no cT1 or cT4 cases. Clinical features associated with DIR included secondary glaucoma (67%), retinal detachment (38%), diffuse vitreous seeds (37%), anterior segment involvement (24%), vitreous haemorrhage (50%) and hyphema (6%). Primary enucleation was the predominant treatment (81%), while 19% initially received systemic chemotherapy, with 6% requiring subsequent enucleation. The 5-year Kaplan-Meier survival rate for cT3 DIR was 82% (95% CI, 78 to 86), significantly lower than the 94% (95% CI, 93 to 95) for cT3 non-DIR cases (pConclusions Approximately 1 in 20 patients with retinoblastoma had DIR, which often presented with glaucoma, anterior segment involvement or intraocular bleeding. DIR was more lethal than non-DIR cT3, with enucleation revealing high-risk pathology.
- Open Access
- 1 June 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 58 (3) , 262-269
Optic disc cupping after circumpapillary Pd-103 slotted plaque radiation therapy
- 1 June 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 58 (3) , 262-269
Open AccessOptic disc cupping after circumpapillary Pd-103 slotted plaque radiation therapy
- Open Access
- 30 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 933-945
Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma
- 30 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 933-945
Open AccessMetastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma
- 25 April 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (4) , 286-288
Reply: Mechanisms of post-radiation optic atrophy with neuroretinal rim thinning
- 25 April 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (4) , 286-288
Reply: Mechanisms of post-radiation optic atrophy with neuroretinal rim thinning
- Open Access
- 15 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 923-932
High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma
- 15 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (8) , 923-932
Open AccessHigh-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma